This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FCSC Fibrocell Science (FCSC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Fibrocell Science Stock (NASDAQ:FCSC) 30 days 90 days 365 days Advanced Chart Get Fibrocell Science alerts:Sign Up Key Stats Today's Range$3.00▼$3.0050-Day Range$3.00▼$3.0052-Week Range$1.45▼$3.28VolumeN/AAverage Volume78,673 shsMarket Capitalization$29.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania. Read More Receive FCSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fibrocell Science and its competitors with MarketBeat's FREE daily newsletter. Email Address FCSC Stock News HeadlinesBest Data Science Bootcamps Online In 2024February 20, 2024 | forbes.comScience & Tech NewsFebruary 6, 2024 | dailymail.co.ukThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 16 at 2:00 AM | Brownstone Research (Ad)What You Need to Know About Becoming a Computer Science MajorSeptember 15, 2023 | usnews.comEpidermolysis Bullosa Therapeutics Market Factual Overview Research Report 2023-2030April 7, 2023 | marketwatch.comOramed PharmaceuticalsJanuary 13, 2023 | forbes.comFibrocell Science (FCSC) Stock Spikes Following Rare Pediatric Disease Treatment DesignationDecember 27, 2022 | thestreet.comSee More Headlines FCSC Stock Analysis - Frequently Asked Questions How were Fibrocell Science's earnings last quarter? Fibrocell Science Inc (NASDAQ:FCSC) released its earnings results on Wednesday, August, 14th. The company reported $1.12 earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $1.30. The firm earned $21.79 million during the quarter. When did Fibrocell Science's stock split? Shares of Fibrocell Science reverse split on Friday, May 25th 2018.The 1-5 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 24th 2018. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of Fibrocell Science own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fibrocell Science investors own include Carlyle Group (CG), Celldex Therapeutics (CLDX), Neos Therapeutics (NEOS), Amarin (AMRN), OPKO Health (OPK), NextTrip (NTRP) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings8/14/2019Today7/16/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FCSC CIK357097 Webfibrocell.com Phone484-713-6000FaxN/AEmployees19Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.45) Trailing P/E RatioN/A Forward P/E Ratio30.00 P/E GrowthN/ANet Income-$10.28 million Net MarginsN/A Pretax MarginN/A Return on Equity23.10% Return on Assets10.56% Debt Debt-to-Equity Ratio0.47 Current Ratio5.09 Quick Ratio5.09 Sales & Book Value Annual Sales$350 thousand Price / Sales83.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book3.06Miscellaneous Outstanding Shares9,760,000Free FloatN/AMarket Cap$29.28 million OptionableOptionable Beta1.67 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:FCSC) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredMajor Rollout of Social Security X?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fibrocell Science Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fibrocell Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.